Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07373613

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
330 (estimated)
Sponsor
Boryung Pharmaceutical Co., Ltd · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.

Conditions

Interventions

TypeNameDescription
DRUGBR1400-1One tablet administered alone
DRUGBR1400-2One tablet administered alone
DRUGBR1400-3One tablet administered alone
DRUGBR1400-4One tablet administered alone
DRUGBR1400-5One tablet administered alone
DRUGBR1400-AOne tablet administered alone
DRUGBR1400-BOne tablet administered alone
DRUGBR1400-COne tablet administered alone

Timeline

Start date
2026-03-01
Primary completion
2027-02-01
Completion
2027-02-01
First posted
2026-01-28
Last updated
2026-01-28

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT07373613. Inclusion in this directory is not an endorsement.

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension (NCT07373613) · Clinical Trials Directory